官方服务：
资源简介：
NGS data of ALK patients in progression to TKIs
应用场景：
创建时间：
2023-05-23
相关数据集
Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1. Homo sapiens
Patients with EGFR-mutant lung adenocarcinomas who initially respond to first-generation TKIs develop resistance to these drugs. A combination of the irreversible TKI afatinib and the EGFR antibody ce
NIAID Data Ecosystem70
WES of mouse cell lines - The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance. WES of mouse cell lines - The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance
In this study, the impact of the Apolipoprotein B mRNA-editing catalytic subunit-like (APOBEC) enzyme APOBEC3B (A3B), on epidermal growth factor receptor (EGFR)-driven lung cancer was assessed. A3B ex
NIAID Data Ecosystem50
RNA-seq of PC9 cells tolerant to gefitinib
EGFR inhibitors (EGFRi) are effective against EGFR mutant lung cancers. The efficacy of these drugs however is mitigated by the outgrowth of resistant cells, most often driven by a secondary acquired
NIAID Data Ecosystem30
BCAT1 Confers Resistance to EGFR TKIs through α-KG-dependent Epigenetic Regulation of the Glycolysis Pathway in NSCLC
BCAT1 Confers Resistance to EGFR TKIs through α-KG-dependent Epigenetic Regulation of the Glycolysis Pathway in NSCLC
integrated proteome resources60
Analysis of gene expression change by gefitinib treatment in gefitinib sensitive PC9 and resistant PC9
We established a gefitinib-resistant cell line (PC-9GR), by serial exposure of gefitinib to PC-9, an originally gefitinib-sensitive lung cancer cell line (PC-9na), for long period.We collected total R
NIAID Data Ecosystem40
